New York, New York–(Newsfile Corp. – December 24, 2024)– Why: Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of the securities of AstraZeneca PLC (NASDAQ:LON:) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Period” date). the chapter”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the court No later than February 21, 2025 In the securities class action lawsuit filed by the company for the first time.
so what: If you purchase AstraZeneca (NASDAQ:) securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
What to do next: To join the AstraZeneca class action, go to https://rosenlegal.com/submit-form/?case_id=1331 or contact Phillip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the court No later than February 21, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the lawsuit.
Why Rosen's Law: We encourage investors to select qualified advisors with a proven track record of success in leadership roles. Often, companies issuing notices do not have similar experience, resources, or any meaningful recognition from their peers. Be wise in choosing advisors. The Rosen Law Firm represents investors throughout the world, focusing its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever settlement of a securities class action lawsuit against a Chinese company at that time. Rosen Law Firm is Ranked #1 by ISS Securities Class an act (WA:) Services for a number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company raised more than $438 million for investors. In 2020, co-founder Lawrence Rosen was named by Law360 as a Titan in the Plaintiffs Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Case details: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) AstraZeneca was involved in insurance fraud in China; (2) as a result, AstraZeneca faced increased legal exposure in China, which ultimately resulted in the President of AstraZeneca China being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca reduced its legal risks; (4) the foregoing, once disclosed, could materially harm AstraZeneca's business activities in China; and (5) as a result, Defendants' statements about their business, operations, and future prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims, investors suffered damages.
To join the AstraZeneca class action, go to https://rosenlegal.com/submit-form/?case_id=1331 and contact Phillip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action.
No category is approved. Until the class is approved, you will not be represented by counsel unless you retain one. You can choose the lawyer of your choice. You can also remain an absent class member and do nothing at this point. An investor's ability to participate in any potential future recovery is not dependent on serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https:/ /www.facebook.com/rosenlawfirm.
Lawyer advertisement. Previous results do not guarantee a similar result.
——————————-
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235195
